| Name | Title | Contact Details |
|---|
Med Assure is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are dedicated to bringing the fashion, comfort and quality of the ready-to-wear market to the functional apparel worn by healthcare professionals. You may have already noticed how Cherokee products bring a little more style and personality to
We hold market leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. Our customers depend on our advanced technologies to help reduce potential complications of skin breakdown and infection, and they rely on our products and services to help manage their conditions every day. Meeting their needs is what motivates us and is a source of tremendous pride for our nearly 9,500 employees who are based in more than 110 countries worldwide. At ConvaTec, we exist to improve the lives of the people we touch. We are committed to helping people with chronic health conditions lead the life they want – giving them more mobility, confidence and freedom. Our vision is to be recognised as the most respected and successful MedTech company, worldwide. To achieve this, we drive for excellence in all that we do – anticipating and addressing our customers` needs with advanced technologies and best-in-class products and services. Our values-based culture helps drive our success. Caring for People: We are passionate about improving people`s lives and put people at the centre of everything we do. Driving Innovation and Excellence: We are dedicated to finding innovative solutions that anticipate and address our customers` needs and to delivering best-in-class execution. Earning Trust: We earn trust by delivering quality products and services that our customers can rely on. Our personal actions underpin this trust – we do what we say we will do.
Vygon Medical is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.